Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | ADK | P55263 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11823190 | 0.74 | NPC1 (0.46) | NISCHMTORGAAMAPTALDH1A1 | |
| SCHEMBL3733802 | 0.73 | GAA (0.45) | GAAMAPTIDO1 | |
| SCHEMBL30476400 | 0.71 | HPGDS (0.36) | GAAMAPT | |
| Chloromethane SCHEMBL28762414 | 0.69 | GAA (0.41) | GAAMAPTALDH1A1 | |
| SCHEMBL11880108 | 0.69 | CYP2A6 (0.42) | GAAMAPTALDH1A1IDO1KDM4E | |
| Benzodiazepine SCHEMBL29144783 | 0.68 | MTOR (0.36) | NISCHMTORADKGAAMAPT | |
| SCHEMBL29441880 | 0.66 | CYP2A6 (0.39) | GAAMAPT | |
| SCHEMBL6370621 | 0.66 | GAA (0.37) | NISCHGAAMAPTALDH1A1KDM4E | |
| SCHEMBL3241604 | 0.65 | MAPT (0.48) | GAAMAPT | |
| SCHEMBL8554754 | 0.65 | GAA (0.48) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040009972-A1 | Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase | BRISTOL-MYERS COMPANY | 2004-01-15 | — | — | US | disclosed |
| WO-2003106628-A2 | BENZODIAZEPINE INHIBITORS OF MITOCHONDIAL F1F0 ATP HYDROLASE AND METHODS OF INHIBITING F1F0 ATP HYDROLASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009972-A1 | Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase | MT-ATP6, MT-CO1, ATP5ME | NISCH 3659/4885MTOR 4450/4885ADK 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.